森萱医药
(920946)
| 流通市值：44.68亿 | | | 总市值：44.70亿 |
| 流通股本：4.27亿 | | | 总股本：4.27亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 160,305,237.6 | 552,577,290.5 | 411,214,920.81 | 260,780,605.31 |
| 营业收入 | 160,305,237.6 | 552,577,290.5 | 411,214,920.81 | 260,780,605.31 |
| 二、营业总成本 | 101,738,509.09 | 390,170,490.59 | 282,805,255.69 | 177,772,448.45 |
| 营业成本 | 77,375,997.93 | 295,091,255.67 | 217,308,292.91 | 134,210,670.19 |
| 税金及附加 | 2,387,504.3 | 8,099,490.94 | 6,365,195.37 | 4,176,589.47 |
| 销售费用 | 4,054,457.31 | 14,099,246.73 | 10,641,996.05 | 7,289,042.53 |
| 管理费用 | 12,445,902.23 | 55,159,378.63 | 39,967,561.02 | 25,665,750.45 |
| 研发费用 | 6,013,677.62 | 30,730,314.45 | 19,946,134.85 | 12,297,427.89 |
| 财务费用 | -539,030.3 | -13,009,195.83 | -11,423,924.51 | -5,867,032.08 |
| 其中:利息费用 | 38,562.98 | 94,345.06 | 75,779.73 | 40,920.96 |
| 其中:利息收入 | 2,195,331.66 | 15,482,191.34 | 13,004,900.32 | 6,382,420.47 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 530,249.8 | 1,754,904.05 | 1,442,640.98 | 854,982.69 |
| 加:投资收益 | 273,435.61 | 959,285.82 | 552,182 | 420,272.41 |
| 资产处置收益 | - | 2,615.92 | 14,997.57 | 4,478.7 |
| 资产减值损失(新) | -1,154,203.92 | -8,929,731.82 | -5,946,841.45 | -4,368,596.75 |
| 信用减值损失(新) | -473,102.06 | 807,657.59 | 592,690.84 | 981,538 |
| 其他收益 | 604,093.79 | 2,647,909.07 | 1,369,887.16 | 1,090,969.98 |
| 四、营业利润 | 58,347,201.73 | 159,649,440.54 | 126,435,222.22 | 81,991,801.89 |
| 加:营业外收入 | 1,416 | 1,000.17 | 0.17 | 0.16 |
| 减:营业外支出 | 5,273.58 | 712,866.56 | 30,800.35 | 5,640.5 |
| 五、利润总额 | 58,343,344.15 | 158,937,574.15 | 126,404,422.04 | 81,986,161.55 |
| 减:所得税费用 | 8,215,058.35 | 21,166,600.74 | 18,228,078.36 | 11,947,895.44 |
| 六、净利润 | 50,128,285.8 | 137,770,973.41 | 108,176,343.68 | 70,038,266.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 50,128,285.8 | 137,770,973.41 | 108,176,343.68 | 70,038,266.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,046,740.52 | 131,484,558.45 | 103,656,049.35 | 67,920,072.39 |
| 少数股东损益 | 3,081,545.28 | 6,286,414.96 | 4,520,294.33 | 2,118,193.72 |
| 扣除非经常损益后的净利润 | 46,275,797.41 | 127,878,609.91 | 100,876,271.35 | 66,192,565.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.31 | 0.24 | 0.16 |
| (二)稀释每股收益 | 0.11 | 0.31 | 0.24 | 0.16 |
| 九、综合收益总额 | 50,128,285.8 | 137,770,973.41 | 108,176,343.68 | 70,038,266.11 |
| 归属于母公司股东的综合收益总额 | 47,046,740.52 | 131,484,558.45 | 103,656,049.35 | 67,920,072.39 |
| 归属于少数股东的综合收益总额 | 3,081,545.28 | 6,286,414.96 | 4,520,294.33 | 2,118,193.72 |
| 公告日期 | 2026-04-29 | 2026-04-22 | 2025-10-29 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |